In this episode of Boba & Biotech, I go for a tasty brown sugar milk tea with Martin Madaus, former CEO of one of the biggest technology providers in our field, Millipore, for a wide-ranging conversation on what actually creates value in life sciences. Martin traces his unconventional path from veterinary medicine to global leadership roles across pharma, diagnostics, and life science tools, and shares hard-earned perspective on platform businesses versus therapeutics, why tool companies often struggle with adoption, and when M&A truly makes sense. He pushes back on the idea that therapeutics are intellectually “superior” to tools and highlights underappreciated technologies like MRD testing and spatial proteomics. Martin also makes a forceful case for moving beyond animal testing in favor of organ-on-chip models. The episode closes with a look at where real clinical impact may come next - from cell therapies to emerging innovation out of China. Martin Madaus is a seasoned public-company CEO, who has led and advised diagnostics and life science tools companies for decades, including serving as Chairman and CEO of Ortho Clinical Diagnostics and as President, Chairman, and CEO of Millipore Corporation, which he led through its $7.2 billion sale to Merck KGaA. Earlier in his career, he was CEO of Roche Diagnostics North America. Dr. Madaus holds a DVM from the University of Munich and a Ph.D. from the Veterinary University of Hannover. Links Armon’s LinkedIn - https://www.linkedin.com/in/armonsharei/  Martin’s LinkedIn - https://www.linkedin.com/in/martin-madaus-3baaa728/  Credits Hosted by Armon Sharei, PhD Research by Julie Kim, MBA Produced by Arielle Nissenblatt of Pinwheel, Carolyn Corbet of Portal  Edited and mixed by David Woje of Pinwheel